Laura Jetter
Nurse Practitioner · Cumming, IANPI 1467964056
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,414 of the $3,885 with a category attached, or 87.9%. 28 manufacturers reported payments, led by AstraZeneca at 24.5% of the total. 2025 is the largest year on record at $1,174, 2.4 times the $498 reported in 2021. Among nurse practitioner clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$952
- Sanofi$833
- Sanofi-aventis U.S. LLC$432
- Takeda Pharmaceuticals U.S.A., Inc.$212
- GSK$208
- Genentech USA, Inc.$201
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,41488%
- Education$47112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $952 |
| Sanofi | 68 | $833 |
| Sanofi-aventis U.S. LLC | 5 | $432 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $212 |
| GSK | 13 | $208 |
| Genentech USA, Inc. | 11 | $201 |
| Pfizer | 7 | $122 |
| Alk-abello, Inc | 7 | $116 |
| Amgen(2 entities) | 6 | $104 |
| Regeneron Healthcare Solutions, Inc. | 4 | $90 |
| Novartis | 4 | $73 |
| CSL Behring | 3 | $72 |
| Galderma Laboratories, L.p. | 4 | $60 |
| Pharming Healthcare, Inc. | 3 | $52 |
| Biocryst US Sales Co., LLC | 3 | $52 |
| Kaleo, Inc. | 3 | $50 |
| Incyte Corporation | 2 | $43 |
| Atricure, Inc. | 1 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Optinose US, Inc. | 2 | $31 |
| Grifols USA, LLC | 1 | $25 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Verona Pharma, Inc. | 1 | $14 |
| USWM, LLC | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Organon | 1 | $8 |
How this compares
$3,885 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 18 | $77,675 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $43,983 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $12,454 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $7,555 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $6,973 |
| Epinephrine | 43 | $6,841 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $5,570 |
| Azelastine Hcl | 157 | $4,758 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,557 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $1,996 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $1,417 |
| Montelukast Sodium | 150 | $1,125 |
| Ventolin HfaAlbuterol Sulfate | 15 | $912 |
| Fluticasone Propionate | 50 | $759 |
| Ipratropium Bromide | 25 | $486 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Arnuity Ellipta | $208 | $53,110100 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $952 | $19,42749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Other nurse practitioner in Cumming
- Nicole MorganDes Moines$106K
- Julie CoffeyIowa City$31K
- Mary JohnsonDavenport$30K
- Megan Hart FernandezCedar Rapids$19K
- Carla HuberCedar Rapids$18K
- Beth ChiaWest Des Moines$15K
- Margaret KinneyRed Oak$13K
- Abbey ModlinDes Moines$12K
- Jonathon HenningsWaterloo$11K
- Michaela JohnsonWaterloo$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.